CSI Market
Sign In | Register

Zivo Bioscience Inc (ZIVO) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ZIVO Annual Cash Flow →
Cash flow patterns shown here provide context for understanding Zivo Bioscience Inc's ability to sustain operations and capital deployment.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2025)
9 Months 		(Jun 30 2025) (Mar 31 2025) (Dec 31 2024) (Sep 30 2024)
Operating Activities
Income0.00
Depreciation & amortization0.00
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Warrants Issued As Payment Of Finance Costs-
Warrants Issued For Finders Fees-
Vendor Settlement-
Amortization Of Prepaid Consulting Fees-
Amortization Of Bond Discount-
Amortization Of Deferred Finance Costs-
Depreciation Expense-
Fair Value Adjustment Of Derivative Liability-
Increase Decrease In Deferred Rent-
Finance Costs Paid In Stock And Warrants-
Finance Cost Paid In Stock And Warrants-
Amortization Of Deferred Finance Cost-
Finance Costs Paid In Warrants Related Party-
Finance Costs Paid In Stock And Warrants-
Deferred Finance Cost Amortization Expense-
Fair Value Adjustment Of Derivative Liability-
Amortization Of Lease Liability-
Warrants And Options Issued For Services Related Parties-
Amortization Of Deferred R D Obligations Participation Agreements-
Increase Decrease In Account Receivable-
Increase Decrease In Operating Lease Liability-0.06
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Accounts Payable0.58
Increase (Decrease) in Accrued Liabilities0.52
Increase (Decrease) in Customer Deposits0.02
Increase (Decrease) in Prepaid Expense-0.13
Other Working Capital0.00
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-3.11
Discontinued operations0.00
Net Cash flow from Operating Activities-2.17
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Proceeds from Sale of Equity Method Investments0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.15
Other borrowing transactions0.00
Long-term debt - borrowings0.25
Long-term debt - repayments-0.10
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.10
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.30
Payment Of Deferred Finance Costs-
Proceeds Of Other Borrowings-
Proceeds From Loans Payable Other-
Finance Costs Paid On Issuance Of11 Convertible Debentures-
Proceeds From Issuance Of11 Convertible Debentures-
Finance Charges Paid On Issuance Of11 Convertible Debt-
Deferred Finance Costs-
Debt Related Commitment Fees And Debt Issuance Costs-
Proceeds From Payments Of Loans Payable Related Parties-
Proceeds From Loan Payable Related Party Net Of Repayments-
Proceeds From Sale Of Common Stock Warrants Participation Agreements-
Expenses Related To Public Offering-
Proceeds From Loans Payable Related Parties-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.69
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-2.17
Total Cash Flow-1.49
4 historic quarters locked

Sign in to unlock the full Zivo Bioscience Inc cash flow history.

Sign In Create Free Account

About Zivo Bioscience Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20250930)
  • Filed with the SEC: November 14, 2025
  • Source: zivo_10q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001654954-25-013095

Figures are derived from filed reports and may be restated. Historical data is subject to revision.